

09 Jan 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: 2023 drug launch highlights; the M&A outlook for the new year; AstraZeneca's China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs?

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 January 2024, including: 2023 US drug launch highlights; the M&A outlook for the new year; [AstraZeneca PLC](#)'s China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs?

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Many Firsts Among The Drugs That Launched In 2023](#)" - Scrip, 1 Jan, 2024.)

(Also see "[Going Into 2024, PWC Predicts Healthy Atmosphere For M&A](#)" - Scrip, 3 Jan, 2024.)

(Also see "[AstraZeneca's Gracell Acquisition Injects New Excitement For Cell Therapy In China](#)" - Scrip, 2 Jan, 2024.)

(Also see "[Stock Watch: The Deal Flow Before Christmas](#)" - Scrip, 2 Jan, 2024.)

(Also see "[Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?](#)" - Scrip, 4 Jan, 2024.)

[Click here to explore this interactive content online](#) 